Drugs that contain Oritavancin Diphosphate
1. Kimyrsa patents expiration
KIMYRSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(5 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 12, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
NCE-1 date: 2023-08-07
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
KIMYRSA family patents
2. Orbactiv patents expiration
ORBACTIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(5 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
NCE-1 date: 2023-08-07
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
ORBACTIV family patents